Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does cyclophosphamide induce bladder cancer?

R M Pearson, M S Soloway

    Urology
    |May 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Cyclophosphamide chemotherapy is linked to a rise in secondary bladder cancers, particularly in patients with blood disorders or those who have undergone organ transplants. Further research is needed to confirm cyclophosphamide

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Editorial: The role of parent-child interactions in developmental psychopathology: methodological and intervention challenges and opportunities.

    Frontiers in child and adolescent psychiatry·2025
    Same author

    The effects of estuarine outflows on coastal marine ecosystems in New South Wales, Australia.

    Marine pollution bulletin·2024
    Same author

    Quantifying the efficacy of an automated facial coding software using videos of parents.

    Frontiers in psychology·2023
    Same author

    Patient tolerability during office cystoscopy and bladder tumor cauterization: a multivariate analysis of risk factors.

    Actas urologicas espanolas·2022
    Same author

    Surveillance and office management of low-grade Ta bladder tumors.

    Actas urologicas espanolas·2022
    Same author

    Thoughts of self-harm in early and late pregnancy in urban South Africa: Investigating prevalence, predictors and screening options.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2021
    Same journal

    Preventing Postpartum Pelvic Floor Dysfunction: Clinical Evidence and Policy Gaps in U.S. Coverage of Pelvic Floor Muscle Therapy.

    Urology·2026
    Same journal

    Editorial Comment on "Through the Eyes of the Applicant: A Qualitative Study of the Urology Residency Match".

    Urology·2026
    Same journal

    Editorial Comment on "A Histopathologic Assessment of Prostate Ductal Anatomy in Relation to Micro-Ultrasound".

    Urology·2026
    Same journal

    Same-Day Discharge Following Multiport Robot-Assisted Simple Prostatectomy: A Prospective Feasibility Study of Outcomes, Costs, and Post-Discharge Healthcare Utilization.

    Urology·2026
    Same journal

    Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer.

    Urology·2026
    Same journal

    Intractable Epistaxis and Severe Hypertension in a Young Woman.

    Urology·2026
    See all related articles

    Area of Science:

    • Oncology
    • Urology
    • Immunology

    Background:

    • Cyclophosphamide (CTX) is a widely used chemotherapy agent.
    • An increasing incidence of secondary primary bladder malignancies has been observed.
    • These malignancies are often associated with lymphoproliferative disorders or immunosuppression.

    Observation:

    • A case of bladder adenocarcinoma in a patient with malignant lymphoma is presented.
    • Literature review of secondary bladder cancers following cyclophosphamide therapy.
    • Studies on increased second primary cancers in lymphoproliferative disorders are discussed.

    Findings:

    • Cyclophosphamide use is temporally associated with bladder neoplasms.
    • Immunosuppression is explored as a factor in second primary malignancies.

    Related Experiment Videos

  • Potential carcinogenic mechanisms of cyclophosphamide include immune suppression and direct effects.

    • Implications:

    • Calls for systematic reporting of bladder tumors in cyclophosphamide-treated patients.
    • Suggests prospective studies to evaluate cyclophosphamide's carcinogenicity.
    • Highlights the need to assess risks in patients receiving cyclophosphamide for non-malignant conditions.